Researches that were done earlier reported that there is a lesser risk of ovarian cancer in users of oral contraceptive measures. The research team headed by Doctor Kirsten Moysich, who is a professor at Roswell Park, gathered data from Ovarian Cancer Association Consortium (OCAC) and assessed it properly to find out the relationship between usage of pre-diagnostic oral contraception and the occurrence of extremely fatal ovarian cancer. They extracted data from twenty case studies, which involved around 580 patients who lost their life within twelve months after verification of them having ovarian cancer. This data was matched with a control group of around 2,279 patients who didn’t have this disease.
After analyzing many confounding factors such as the age of the patient, and whether they had given birth, the outcomes showed that any past connection with the use of oral contraceptives was linked with a decrease of 46 percent in the chances of dying within twelve months of diagnosis.
This work of the team is considered to be the first extensive study which took place at multiple locations around the world in order to determine how the use of oral contraceptives is linked with the risk of acquiring an extremely fatal ovarian cancer.
Jennifer Mongiovi, who is the first author of this research and a co-worker of Doctor Moysich, stated the following: “The longer the history of oral contraceptive use, the greater the protection we observed in terms of reduced chance of dying from aggressive ovarian cancer. For every five years of use, we observed 32% lower odds of highly fatal disease, compared to 13% for all ovarian cancer as previously reported by other researchers. This association also varies by histological subtype, and was found most protective for highly fatal endometrioid ovarian cancers.”
Doctor Moysich commented on this study: “Our results provide strong evidence that this is an area worthy of further study so that we can better understand the mechanisms behind this association and identify specific groups of people who may benefit most from this chemopreventive strategy.”